β-4-Gal-T4 Activators encompass a variety of chemical compounds that enhance the enzyme's functionality in glycosylation processes, primarily within the Golgi apparatus. Adenosine Triphosphate (ATP) and Uridine Diphosphate Galactose (UDP-Galactose) play direct roles; ATP provides essential energy for the galactosylation reactions, while UDP-Galactose acts as the direct substrate, supplying the galactose moiety. Manganese(II) chloride, a crucial cofactor, stabilizes the enzyme's structure and enhances its catalytic efficiency. The structural disruption of the Golgi apparatus by Brefeldin A indirectly increases substrate accessibility to β-4-Gal-T4, thus enhancing its activity. Forskolin and the calcium ionophore A23187 influence intracellular signaling pathways that modulate Golgi function; Forskolin raises cAMP levels, which can upregulate the transport and processing of glycoproteins, whereas A23187 elevates calcium levels, indirectly enhancing glycosylation activity. Nitrophenyl-β-D-galactopyranoside serves as a synthetic substrate, facilitating the measurement and increase of the enzyme's activity. Thapsigargin, by increasing cytosolic calcium through SERCA inhibition, affects calcium-dependent signaling pathways, indirectly influencing β-4-Gal-T4 activity.
Moreover, 1,2-Dioctanoyl-sn-glycerol (DOG), as a PKC activator, and Monensin, by altering intracellular ion concentrations, modulate the Golgi's function, indirectly influencing β-4-Gal-T4's role in glycosylation. N-Butyldeoxynojirimycin and Swainsonine, by inhibiting specific glycosidases and mannosidases respectively, alter glycoprotein processing, which can lead to an accumulation of substrates for β-4-Gal-T4, thereby enhancing its activity. These compounds collectively contribute to the effective functioning of β-4-Gal-T4, each affecting different aspects of its activation and activity. Through a combination of direct substrate provision, cofactor interaction, modulation of cellular signaling, and alteration in substrate processing within the Golgi, these activators collectively ensure the effective and efficient galactosylation activity of β-4-Gal-T4, crucial for proper glycoprotein function.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
ATP | 56-65-5 | sc-507511 | 5 g | $17.00 | ||
ATP provides energy for β-4-Gal-T4's galactosylation reactions, ensuring a constant energy supply for transferring galactose to glycoproteins and glycolipids, thereby enhancing enzymatic activity. | ||||||
UDP-α-D-Galactose disodium salt | 137868-52-1 | sc-286849 sc-286849A | 10 mg 50 mg | $104.00 $198.00 | 1 | |
As a direct substrate for β-4-Gal-T4, UDP-Galactose supplies the galactose moiety for glycosylation, essential for β-4-Gal-T4’s functional activity. | ||||||
Manganese(II) chloride beads | 7773-01-5 | sc-252989 sc-252989A | 100 g 500 g | $19.00 $31.00 | ||
Mn2+ acts as a cofactor, stabilizing β-4-Gal-T4’s structure and enhancing catalytic efficiency by facilitating substrate orientation, thus increasing enzymatic activity. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
By disrupting the Golgi apparatus, Brefeldin A indirectly increases substrate accessibility to β-4-Gal-T4, enhancing its functional activity in glycosylation processes. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin raises cAMP levels, indirectly enhancing β-4-Gal-T4's activity by upregulating glycoprotein transport and processing in the Golgi. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187 increases intracellular calcium levels, influencing Golgi function and indirectly enhancing β-4-Gal-T4 activity in glycosylation by affecting glycoprotein trafficking and processing. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
By inhibiting SERCA and increasing cytosolic calcium, Thapsigargin indirectly influences β-4-Gal-T4 activity through calcium-dependent signaling pathways that regulate Golgi function and glycoprotein processing. | ||||||
1,2-Dioctanoyl-sn-glycerol | 60514-48-9 | sc-202397 sc-202397A | 10 mg 50 mg | $47.00 $254.00 | 2 | |
DOG, a PKC activator, indirectly enhances β-4-Gal-T4's functional activity in glycosylation by influencing Golgi function and vesicular trafficking. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $155.00 $525.00 | ||
As an ionophore altering intracellular pH and ion concentrations, Monensin affects Golgi function, indirectly increasing β-4-Gal-T4's activity in glycosylation by enhancing glycoprotein trafficking and processing. | ||||||
Deoxynojirimycin | 19130-96-2 | sc-201369 sc-201369A | 1 mg 5 mg | $73.00 $145.00 | ||
This compound inhibits glucosidases in N-linked glycan processing, leading to altered glycoprotein processing in the Golgi and potentially enhancing β-4-Gal-T4 activity by changing substrate availability. | ||||||